T\_HSC\_S1PR3\_OE\_UP, XIE\_ST\_HSC\_S1PR3\_OE\_UP

CHIANG LIVER CANCER SUBCLASS CTNNB1 DN, CHIANG LIVER CANCER SUBCLASS CTNNB1 DN TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_8D\_UP, TAKEDA\_TARGETS\_OF\_NUP98\_HOXA9\_FUSION\_8D\_UP TAKEDA TARGETS OF NUP98 HOXA9 FUSION 10D UP, TAKEDA TARGETS OF NUP98 HOXA9 FUSION 10D UP MANNE COVID19 NONICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_NONICU\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP TAKEDA TARGETS OF NUP98 HOXA9 FUSION 3D UP, TAKEDA TARGETS OF NUP98 HOXA9 FUSION 3D UP MEISSNER\_NPC\_HCP\_WITH\_H3K4ME3\_AND\_H3K27ME3, MEISSNER\_NPC\_HCP\_WITH\_H3K4ME3\_AND\_H3K27ME3 VECCHI GASTRIC CANCER ADVANCED VS EARLY UP, VECCHI GASTRIC CANCER ADVANCED VS EARLY UP GUTIERREZ CHRONIC LYMPHOCYTIC LEUKEMIA DN, GUTIERREZ CHRONIC LYMPHOCYTIC LEUKEMIA DN GAVIN\_FOXP3\_TARGETS\_CLUSTER\_P7, GAVIN\_FOXP3\_TARGETS\_CLUSTER\_P7 FONTAINE\_PAPILLARY\_THYROID\_CARCINOMA\_UP, FONTAINE\_PAPILLARY\_THYROID\_CARCINOMA\_UP AZARE\_NEOPLASTIC\_TRANSFORMATION\_BY\_STAT3\_UP, AZARE\_NEOPLASTIC\_TRANSFORMATION\_BY\_STAT3\_UP MANNE\_COVID19\_COMBINED\_COHORT\_VS\_HEALTHY\_DONOR\_PLATELETS\_UP, MANNE\_COVID19\_COMBINED\_COHORT\_VS\_HEALTHY\_DONOR\_PLATE REACTOME\_EICOSANOID\_LIGAND\_BINDING\_RECEPTORS, REACTOME\_EICOSANOID\_LIGAND\_BINDING\_RECEPTORS REACTOME SIGNALING BY KIT IN DISEASE, REACTOME SIGNALING BY KIT IN DISEASE REACTOME TRAF6 MEDIATED IRF7 ACTIVATION, REACTOME TRAF6 MEDIATED IRF7 ACTIVATION MANNE COVID19 ICU VS HEALTHY DONOR PLATELETS UP, MANNE COVID19 ICU VS HEALTHY DONOR PLATELETS UP REACTOME\_SIGNALING\_BY\_PDGF, REACTOME\_SIGNALING\_BY\_PDGF REACTOME REGULATION OF IFNA SIGNALING, REACTOME REGULATION OF IFNA SIGNALING WP\_SARS\_CORONAVIRUS\_AND\_INNATE\_IMMUNITY, WP\_SARS\_CORONAVIRUS\_AND\_INNATE\_IMMUNITY WP\_PATHWAYS OF NUCLEIC\_ACID\_METABOLISM\_AND\_INNATE\_IMMUNE\_SENSING, WP\_PATHWAYS OF NUCLEIC\_ACID\_METABOLISM\_AND\_INNAT REACTOME\_MATURATION\_OF\_NUCLEOPROTEIN, REACTOME\_MATURATION\_OF\_NUCLEOPROTEIN REACTOME TRAF3 DEPENDENT IRF ACTIVATION PATHWAY, REACTOME TRAF3 DEPENDENT IRF ACTIVATION PATHWAY REACTOME\_NICOTINAMIDE\_SALVAGING, REACTOME\_NICOTINAMIDE\_SALVAGING GESERICK TERT TARGETS DN, GESERICK TERT TARGETS DN LU\_IL4\_SIGNALING, LU\_IL4\_SIGNALING HOOI\_ST7\_TARGETS\_DN, HOOI\_ST7\_TARGETS\_DN ZHAN MULTIPLE MYELOMA SPIKED, ZHAN MULTIPLE MYELOMA SPIKED KRIEG\_KDM3A\_TARGETS\_NOT\_HYPOXIA, KRIEG\_KDM3A\_TARGETS\_NOT\_HYPOXIA BIOCARTA RANKL PATHWAY, BIOCARTA RANKL PATHWAY REACTOME SIGNALING BY PDGFR IN DISEASE, REACTOME SIGNALING BY PDGFR IN DISEASE KYNG\_ENVIRONMENTAL\_STRESS\_RESPONSE\_NOT\_BY\_GAMMA\_IN\_OLD, KYNG\_ENVIRONMENTAL\_STRESS\_RESPONSE\_NOT\_BY\_GAMMA\_IN\_OLD BEGUM\_TARGETS\_OF\_PAX3\_FOXO1\_FUSION\_DN, BEGUM\_TARGETS\_OF\_PAX3\_FOXO1\_FUSION\_DN LEE SP4 THYMOCYTE, LEE SP4 THYMOCYTE REACTOME INTERLEUKIN 20 FAMILY SIGNALING, REACTOME INTERLEUKIN 20 FAMILY SIGNALING ZHAN\_MULTIPLE\_MYELOMA\_LB\_DN, ZHAN\_MULTIPLE\_MYELOMA\_LB\_DN PID EPHRINB REV PATHWAY, PID EPHRINB REV PATHWAY